CURRENT STATUS
The first disease-specific drugs for rare kidney diseases have arrived. Sparsentan (FILSPARI) won full FDA approval for IgA nephropathy and FSGS. Finerenone and SGLT2 inhibitors dramatically slow diabetic kidney decline. Complement inhibitors target IgAN and C3 glomerulopathy, and CRISPR/RNA approaches for polycystic kidney disease are advancing.
KEY BREAKTHROUGHS
Sparsentan (FILSPARI) β first non-immunosuppressive drug fully FDA-approved for IgA nephropathy and FSGS, preserving kidney function
Finerenone (Kerendia) β slows diabetic kidney disease progression and cardiovascular events
SGLT2 inhibitors (dapagliflozin, empagliflozin) β proven to slow CKD progression even without diabetes
Complement inhibitors (e.g., iptacopan) advancing for IgA nephropathy and C3 glomerulopathy
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
KEY ORGANIZATIONS
KEY CLINICAL TRIALS
Iptacopan β Factor B Inhibitor for IgA Nephropathy (APPLAUSE-IgAN, Phase 3)
ViewNovartis
An oral complement Factor B inhibitor that dials down the alternative complement pathway driving IgA nephropathy, aiming to reduce proteinuria and preserve kidney function without broad immunosuppression.
Tolvaptan & Next-Gen Therapies for Polycystic Kidney Disease
ViewOtsuka / academic consortia
Building on tolvaptan (the first drug to slow ADPKD cyst growth), trials are testing RNA- and metabolism-targeted approaches to further slow kidney enlargement and delay dialysis in polycystic kidney disease.
TIMELINE ESTIMATE
IgAN / FSGS / diabetic CKD slowing: available now. Functional halt of progression: 3β6 years. Regenerative / bioengineered kidneys: 8β15 years.